Amicus Therapeutics

Latest news

• FDA Approves Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) for the Treatment of Late-Onset Pompe Disease
  28 September 2023
• U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
  28 October 2022
• Amicus Therapeutics Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference
  16 March 2022
• The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease
  18 November 2021
• U.S. FDA Accepts Filings for Amicus’ AT-GAA for the Treatment of Pompe Disease
  29 September 2021
• Amicus’ AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study
  11 February 2021
• Amicus Therapeutics Initiates Rolling Biologic License Application to the U.S. Food and Drug Administration for AT-GAA in Late-Onset Pompe Disease
  1 December 2020
• U.S. FDA Grants Breakthrough Therapy Designation (“BTD”) to Amicus’ AT-GAA in Late Onset Pompe Disease
  25 February 2019
• Amicus Therapeutics Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease
  10 September 2018

Drugs Associated with Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. manufactures, markets and/or distributes more than 3 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.